Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Payables (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Payables for 5 consecutive years, with $507000.0 as the latest value for Q4 2025.

  • For Q4 2025, Payables fell 86.11% year-over-year to $507000.0; the TTM value through Dec 2025 reached $507000.0, down 86.11%, while the annual FY2025 figure was $507000.0, 86.11% down from the prior year.
  • Payables hit $507000.0 in Q4 2025 for Kezar Life Sciences, down from $911000.0 in the prior quarter.
  • Across five years, Payables topped out at $8.3 million in Q4 2023 and bottomed at $507000.0 in Q4 2025.
  • Average Payables over 5 years is $2.7 million, with a median of $2.3 million recorded in 2022.
  • Year-over-year, Payables soared 232.84% in 2023 and then crashed 86.11% in 2025.
  • Kezar Life Sciences' Payables stood at $2.0 million in 2021, then grew by 22.24% to $2.5 million in 2022, then skyrocketed by 232.84% to $8.3 million in 2023, then crashed by 55.75% to $3.7 million in 2024, then plummeted by 86.11% to $507000.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $507000.0, $911000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.